London, UK, 9 June 2008 – Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce the publication of Bioscience Hypotheses (http://www.sciencedirect.com/science/journal/17562392), a new journal for radical hypotheses on topics throughout the life sciences.
The aim of the journal is to stimulate innovation by choosing work that is interesting and challenging, and provides a clear and coherent argument with a testable conclusion. Bioscience Hypotheses is edited by Dr William Bains, biotechnology entrepreneur and innovator, and visiting lecturer at the University of Cambridge.
The journal welcomes papers that:
- deliver new insight into the understanding or application of biology that could be of interest to a wide life science readership
- are clear, coherent, and lay out an argument that is easy to follow
- are not incompatible with known fact (although they may contest the interpretation of those facts)
- provide an interpretation, hypothesis or solution that is testable.
Papers that do not provide a means of testing their conclusion, or differentiating their conclusion from other explanations, will be rejected. Papers that provide some preliminary data (itself perhaps not sufficiently robust to be published as an independent paper, but nevertheless rigorously collected) will be welcomed. However, preliminary data are not a requirement for publication, and Bioscience Hypotheses is not a forum for new experimental results unless they are supporting a broader theoretical structure.
Papers are not subject to standard peer review, but are selected by the Editor on the basis of the criteria laid out above. The journal explicitly does not publish papers addressing medical issues, which should continue to be directed to the sister journal Medical Hypotheses.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Journal
Bioscience Hypotheses